Neurocrine Biosciences
NBIX
#1634
Rank
A$18.89 B
Marketcap
A$188.31
Share price
0.10%
Change (1 day)
2.33%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Earnings for Neurocrine Biosciences (NBIX)

Earnings in 2024: A$0.87 Billion

According to Neurocrine Biosciences 's latest financial reports the company's current earnings are A$2.68 Billion. In 2024 the company made an earning of A$0.87 Billion, an increase over its 2023 earnings that were of A$0.44 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Neurocrine Biosciences from 1996 to 2024

Annual earnings

Year Earnings Change
2024A$0.87 B96.41%
2023A$0.44 B41.13%
2022A$0.31 B73.74%
2021A$0.18 B-8.82%
2020A$0.19 B77.78%
2019A$0.11 B49.83%
2018A$74.49 M-142.57%
2017-A$0.18 Billion-14.73%
2016-A$0.21 Billion53.15%
2015-A$0.14 Billion46.25%
2014-A$91.63 Million29.66%
2013-A$70.67 Million-3530.8%
2012A$2.05 M-95.73%
2011A$48.25 M
2009-A$67.84 Million-45.38%
2008-A$0.13 Billion-58.87%
2007-A$0.31 Billion87.3%
2006-A$0.17 Billion351.97%
2005-A$35.67 Million-52.09%
2004-A$74.45 Million-10.98%
2003-A$83.63 Million
2001-A$62.43 Million
1999-A$28.16 Million108.32%
1998-A$13.52 Million
1996A$4.12 M

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Pfizer
PFE
A$16.85 B 1,932.24%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
A$2.36 B 184.64%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
A$32.01 B 3,758.64%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
A$37.18 M-95.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
-A$59.41 Million-107.16%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
A$71.9 M-91.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
-A$6.83 Million-100.82%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
A$2.25 B 171.24%๐Ÿ‡ฌ๐Ÿ‡ง UK